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Factors involved in the effects of losartan on endothelial dysfunc-
tion induced by aging in SHR. In the present study we investi-
gated the effects of losartan (10 mg/kg/day; 12 weeks) on acetyl-
choline (Ach) induced relaxations in isolated mesenteric vascular
beds (MVB) from adult and elderly spontaneous hypertensive rats
(SHR). Experiments were done in absence or presence of either
the NO synthesis inhibibitor, L-NAME (1025 mol/liter),
L-NAME 1 indomethacin (1025 mol/liter) or L-NAME 1 indo-
methacin 1 KCl (1025 mol/liter), to evaluate the participation of
the factors (NO, PGs and EDHF, respectively) mediating Ach-
relaxations. Systolic blood pressure levels were comparable in
both groups. However, urinary nitrites excretion and Ach-re-
sponse was lower in elderly than in adult SHR. The presence of
L-NAME and L-NAME 1 indomethacin only reduced Ach-
relaxations in untreated elderly SHR. Further addition of KCl to
the perfusion media totally blunted Ach-relaxation in both
groups. The calculated participation of endothelium-derived hy-
perpolarizing factor (EDHF) in Ach-relaxations was higher than
that of nitric oxide (NO) and prostaglandins in both groups,
although the EDHF component was lower in elderly when
compared to adult SHR. Losartan treatment reduced blood
pressure levels and enhanced dose-related Ach-relaxations and
urinary nitrites in both groups. Presence of L-NAME and L-
NAME 1 indomethacin blunted the enhancements induced by
losartan on Ach-relaxations in both adult and elderly SHR.
Further addition of KCl to the perfusion media totally blunted
Ach-relaxation in both groups. The calculated participation of NO
in Ach-relaxations was increased by losartan in both groups.
Neither EDHF or prostanoids (PGs) components were clearly
affected by losartan. In conclusion, (1) diminished EDHF avail-
ability accounts for the reduced Ach-relaxations produced by
aging in MVB from SHR; (2) the enhancement of Ach-relaxations
produced by losartan seems to be dependent on an increased NO
availability; and (3) angiotensin II via angiotensin I type 1
receptor (AT1) plays an important role in the deleterious conse-
quences of aging on endothelial function in SHR.
Hypertension has been shown to be associated with
functional and structural changes in the vessel wall. Nu-
merous studies have shown decreased endothelium-depen-
dent relaxations [1, 2] and increased endothelium-depen-
dent contractions [3–5] in both hypertensive patients and
animal models of hypertension [1, 3, 6–8]. Decreased
availability of either nitric oxide (NO), vasodilator prosta-
glandins or endothelium-derived hyperpolarizing factor
(EDHF), as well as enhanced endothelium-derived con-
tracting factors (EDCFs) seem to account for endothelial
dysfunction in hypertension [9–12]. Structural alterations
of the vessel wall could also account for the observed
alterations of endothelial function in hypertension [13–15].
Aging is able to produce endothelial dysfunction and
structural alterations in the vessel wall of both normoten-
sive and hypertensive rats [10, 16–21]. The understanding
of the mechanisms underlying the effects of aging on
endothelial function in spontaneous hypertensive rats
(SHR) has been precluded by the differential participation
of factors regulating vascular function in different vascular
territories used in the studies. Consequently, a first aim of
this study was to evaluate the effects of aging on the
different factors (NO, prostanoids, EDHF) mediating en-
dothelium-dependent relaxations to acetylcholine (Ach) in
perfused mesenteric vascular beds (MVB) from adult and
elderly SHR.
Angiotensin II (Ang II) seems to play an important role
in the vascular alterations induced by aging in SHR, since
angiotensin converting enzyme (ACE) activity has been
found elevated in aged SHR [22]. Furthermore, treatments
with both ACE inhibitors and angiotensin I type-1 receptor
(AT1) antagonists were able to improve endothelial dys-
function in aortic rings from SHR [9]. In addition, ACE
inhibitors have been shown to increase endothelium-de-
pendent relaxations in resistance arteries from SHR by
enhancing EDHF availability [23]. However, the mecha-
nisms underlying the effects of AT1 receptor antagonists on
endothelium-dependent relaxations in resistance arteries
from adult and elderly SHR are not well known. The
present study also aimed to evaluate which factors mediate
the improvement in Ach-relaxations produced by pro-
longed treatment with the AT1 receptor antagonist, losar-
tan, in MVB from adult and elderly SHR.
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Adult (6 months old; N 5 16) and elderly (24 months
old; N 5 16) male SHR (Charles River, Barcelona, Spain)
maintained under controlled light and temperature condi-
tions were used for the study. The animals were fed a
normal rat chow (A.04; Panlab, Barcelona, Spain) and had
free access to tap water. Rats of each age group were
treated for 12 consecutive weeks with losartan (10 mg/kg/
day) given in drinking water. The dose of losartan was
chosen from previous studies [9]. Systolic blood pressure
(BP) was estimated basally and at week 12 of treatment by
a tail-cuff pletysmograph (Narco Bio-Systems, Houston,
TX, USA) as previously described [9]. At the end of the
treatment period, relaxing responses to; 10212 to 1027 mol)
in MVB were studied as described below. All experimental
procedures were approved by the Animal Care and Use
Commitee from Complutense University, according to the
guidelines for ethical care of experimental animals of the
European Union.
Vascular reactivity in mesenteric vascular beds
After the rats were killed, the superior mesenteric artery
was isolated at its junction with the abdominal aorta and
freed of fat and connective tissue. The mesentery was
gently separated from the intestinal wall and perfused at
constant flow (2 ml/min) with an oxygenated (95% O2 -
5%CO2) Kreb’s bicarbonate buffer of the following com-
position (in mmol/liter): NaCl 118.5, KCl 4.7, CaCl2 2.8,
KH2PO4 1.1, NaHCO3 25.0 and glucose 11.1, at 37°C. Then
the mesentery was removed from the animal and connected
to a pressure transducer (model P23XL; Spectromed,
Oxnard, CA, USA). Perfussion pressure was continuosly
recorded on a polygraph (7E; Grass Instrument, Quincy,
MA, USA) for the rest of the experiment. A bubble trap
system removed any air bubbles in the perfusate. Since flow
was maintained at a constant rate, changes in perfusion
pressure were used as an index of changes in the resistance
of the artery, and a rise or a decrease in the perfusion
pressure indicated either vasoconstriction or vasodilation,
respectively. After an equilibration period of 30 minutes,
the effects on perfusion pressure of arterial injections of
KCl (60 mmol), or angiotensin II (1 nmol) were examined.
Afterwards, the mesenteric vascular beds were continously
perfused with phenylephrine (1025 mol/liter). When steady
contraction was reached, a dose-relaxation curve to acetyl-
choline (10212 to 1027 mol) was performed at three to five
minute intervals. The NO synthesis inhibitor NG-nitro-L-
arginine methyl ester (L-NAME; 1025 mol/liter), was then
infused for the remainder of the experiment. Once the
perfusion pressure had stabilized, a dose-relaxation curve
to acetylcholine (10212 to 1027 mol) was again performed.
The inhibitor of the cyclooxygenase, indomethacin (1025
mol/liter) was latter added to the perfusate and a dose-
relaxation curve to acetylcholine (10212 to 1027 mol) was
done when the perfusion pressure reached a steady level.
Finally, KCl (6 3 1025 mol/liter) was added to the medium
and the response to Ach was again verified.
Urinary nitrite excretion
Rats were housed in individual metabolic cages for
24-hour urine collection. Concentrations of nitrites in urine
samples were measured in duplicate by the Griess reaction
as previously published [24], and the results were expressed
as 24-hour excretion rates. Since urinary excretion of
nitrites has been shown to directly correlate with elevations
or reductions in NO release by endothelium-dependent
vasodilators, we used this measurement as an index of NO
production.
Drugs
Losartan was a gift from MSD Espan˜a, SA (Madrid,
Spain). The rest of the drugs were purchased from Sigma
Chemial Co. (St. Louis, MO, USA). Stock solutions of
drugs were prepared in distilled water and diluted to the
desired concentration with buffer immediately before the
experiment.
Calculations and statistical analysis
Relaxing responses are expressed as percent reduction of
the phenylephrine-preconstricted state. All results are ex-
pressed as mean 6 SEM of N 5 8 rats, unless otherwise
specified. Single variable comparisons were made using a
one-way analysis of variance; all other data were analyzed
by two-way analysis of variance for multiple comparisons,
followed by a Newman-Keuls test if differences were noted.
The null hypothesis was rejected when the P value was less
than 0.05. Area under dose-response curves to Ach in the
absence and presence of L-NAME, L-NAME 1 indometh-
acin and L-NAME 1 indomethacin 1 KCl were used to
calculate approximate participation of either NO, prosta-
noids (PGs) or EDHF in these relaxations.
RESULTS
Blood pressure
Systolic BP levels in both adult and elderly rats were
comparable (196 6 6 vs. 200 6 9 mm Hg, respectively).
Losartan treatment reduced (P , 0.05) systolic BP levels in
both groups in a similar extent (162 6 4, adult vs. 160 6 9,
elderly, mm Hg).
Urinary nitrites excretion
Twenty-four-hour urinary nitrite excretion was markedly
lower (P , 0.05) in elderly than in adult rats (8.8 6 3.8 vs.
54.4 6 15.7 nmol/24 hr, respectively). Treatment with
losartan increased urinary nitrites excretion in both groups,
although values in elderly rats were still higher than those
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in adult rats (64.3 6 18.2 vs. 128 6 25.6 nmol/24 hr,
respectively).
Vascular reactivity in mesenteric vascular beds
Table 1 shows perfusion pressure values in MVB from
both groups basally and in response to KCl, Ang II and
phenylephrine (PE). Basal perfusion pressure and the
increase in perfusion pressure induced by KCl (60 mmol)
were lower (P , 0.05) in elderly than in adult SHR. By
contrast, the increase in perfusion pressure induced by Ang
II was markedly higher (P , 0.05) in elderly than in adult
rats. Continuous infusion of PE induced a similar increase
in perfusion pressure in both groups. Losartan treatment
did not significantly affect perfusion pressure values either
basally, after the KCl bolus or during the PE infusion in any
group. However, losartan treatment totally blunted the
response to Ang II in both age groups. The addition of
L-NAME on top of PE increased perfusion pressure, which
reached similar levels in all groups (untreated rats, adult
410 6 73 and elderly 485.6 6 98; treated rats, adult 441.5 6
80 and elderly 637 6 160% of the response to KCl). By
contrast, the subsequent addition of indomethacin did not
increase perfusion pressure further in any group (data not
shown).
Dose-related response to Ach was lower (P , 0.05) in
untreated elderly than in untreated adult rats (Fig. 1).
Likewise, sensitivity to Ach was also lower (P , 0.05) in
untreated elderly than in adult SHR, as shown by the
smaller pD2 values (Table 2). Presence of L-NAME in the
perfusion media only diminished (P , 0.05) the maximal
Table 1. Perfusion pressure values basally and in response to KC1 (60 mmol), angiotensin II (Ang II; 1 nmol) and phenylephrine (PE; 1025 mol/
liter) in mesenteric vascular beds from adult and senescent spontaneously hypertensive rats untreated and treated with losartan
Parameters
Untreated SHR Treated SHR
Adult Elderly Adult Elderly
Basal mm Hg 11.60 6 0.68 3.82 6 0.88a 12.59 6 0.25 3.50 6 0.62a
KC1 mm Hg 35.21 6 6.24 6.73 6 4.07a 43.92 6 8.83 5.72 6 2.10a
Ang II % KC1 contraction 21.07 6 4.56 233.51 6 30.23a 2.28 6 1.55b 6.71 6 4.81b
PE % KC1 contraction 197.71 6 44.51 262.92 6 47.71 201.61 6 56.42 312.1 6 58
Values express means 6 SEM.
a P , 0.05 vs. adult rats
b P , 0.05
Fig. 1. Concentration-response curves for relaxation induced by acethylcholine (10212 to 1027 mol) in isolated mesenteric vascular beds from adult
(A) and elderly (B) spontaneously hypertensive rats. Mesenteric vascular beds were precontracted with a solution containing phenylephrine (1025
mol/liter) in the absence (F) or presence of either L-NAME (1025 mol/liter; f) or L-NAME 1 indomethacin (1025 mol/liter; ). The relaxation is
expressed as a percentage of the reference constrictor response. Values express means 6 SEM. *P , 0 05 versus control group. Bar graphs (insert)
represent the participation (arbitrary units) of EDHF, NO and PGs in the relaxation induced by acetylcholine in MVB adult and elderly SHR.
Participation was calculated from the respective area under the curve in absence or presence of either L-NAME or L-NAME 1 indomethacin.
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response to Ach in untreated elderly SHR (Fig. 1 and Table
2). Addition of indomethacin further reduced the dose-
related response to Ach (Fig. 1). pD2 values were not
affected either by L-NAME or by L-NAME 1 indometh-
acin in any untreated group (Table 2). Further addition of
KCl to the perfusion media totally blunted Ach-relaxation
in both groups (data not shown). The calculated approxi-
mate participation of EDHF in Ach-relaxations was mark-
edly higher than that of NO and PGs in both untreated
groups. This component of Ach-relaxation was diminished
in elderly when compared to adult SHR (Fig. 1).
Treatment with losartan enhanced (P , 0.05) dose-
related relaxations to Ach in both groups, but enhanced
pD2 only in elderly SHR (Fig. 2 and Table 2). Presence of
both L-NAME and L-NAME 1 indomethacin in the
perfusion media blunted the enhancements induced by
losartan in both groups (Fig. 2 and Table 2). Further
addition of KCl in the perfusion media totally blunted
Ach-relaxations in all groups (data not shown). Losartan
treatment enhanced the calculated approximate participa-
tion of NO in Ach-relaxations in both groups. However,
participation of either EDHF or PGs in Ach-relaxation
were not clearly modified by losartan treatment in any
group.
DISCUSSION
The present study shows that prolonged treatment with
the AT1 receptor antagonist, losartan, was able to enhance
Ach-induced relaxations in MVB from both adult and
elderly SHR. These effects appear to be dependent on an
increased availability of NO, regardless the main factor
responsible for Ach-relaxations in MVB from untreated
SHR is EDHF.
The present study confirms previously published results
showing that in MVB from both adult and elderly SHR the
vasorelaxation induced by Ach is mainly dependent on
EDHF [25, 26]. A limited participation of NO is also
suggested, since addition of the NO synthase inhibitor
L-NAME slightly affected maximal relaxation to Ach only
in elderly rats. In addition, vasodilatory prostanoids, such
as PGI2, seems to play a certain mediatory role in the
relaxation to Ach only in elderly SHR, as suggested by the
reduced response in presence of L-NAME 1 indomethacin
observed in these animals. This rules out the existance of an
arachidonic acid-derived contracting factor playing against
the vasodilatory mediators of Ach.
The study also shows that aging was able to reduce
endothelium-dependent relaxations in response to Ach in
SHR [10, 27, 28]. This effect was mainly due to a reduction
in EDHF availability, as suggested in previously published
reports [27]. Moreover, the participation of an arachidonic
acid-derived contracting factor in this impairment can be
excluded, since Ach-relaxation was not enhanced in pres-
ence of L-NAME 1 indomethacin in elderly SHR. Conse-
quently, it could be proposed that duration of hypertension
impairs endothelium-dependent relaxation in MVB from
SHR by preferentially reducing EDHF availability.
Other mechanisms possibly responsible for the reduction
of Ach-relaxations induced by aging in SHR could be
related to the enhanced response to exogenous Ang II
observed in elderly rats. It has been shown that stimulation
of AT1 receptors by Ang II produces direct vasoconstric-
tion, facilitates sympathetic activity, enhances smooth mus-
cle cell proliferation and growth, stimulates endothelin-1
and TXA2 production by endothelial cells, and increases
vascular superoxide production via membrane NADH/
NADPH oxidase activation [29–32]. All these mechanisms
linked to AT1 receptors, could have contributed to the
effects of aging on Ach-relaxations in MVB from SHR,
since the response to Ang II was exaggerated in elderly
SHR. This notion is supported by the fact that losartan was
able to ameliorate Ach-relaxations in MVB from elderly
SHR, and further suggests that blockade of the mecha-
nisms depending on AT1 receptor activation are related
Table 2. Maximal responses (%) and pD2 values from dose-related relaxations to acetylcholine (10
212 to 1027 mol) of phenylephrine (PE; 1025
mol/liter) contracted beforehand mesenteric vascular beds from adult and elderly spontaneously hypertensive rats untreated and treated with
losartan, basally and in presence of L-NAME (1025 mol/liter) or L-NAME 1 indomethacin (1025 mol/liter)
Parameters
Untreated SHR Treated SHR
Adult Elderly Adult Elderly
Basal
pD2 10.89 6 0.28 9.25 6 0.16
a 10.38 6 0.25 9.94 6 0.14ab
Maximal response 68.11 6 4.64 55.49 6 2.87a 78.84 6 4.93b 66.72 6 7.52b
1 L-NAME
pD2 10.73 6 0.10 9.51 6 0.22
a 9.21 6 0.19c 8.87 6 0.18ac
Maximal response 70.14 6 6.75 40.55 6 6.86ac 57.81 6 7.08c 45.12 6 3.73ac
1 L-NAME 1 INDO
pD2 10.22 6 0.40 9.03 6 0.27
a 9.5 6 0.16c 8.72 6 0.21ac
Maximal response 69.04 6 3.5 35.32 6 7.72ac 61.87 6 8.58ac 37.62 6 6.98ac
Values express means 6 SEM.
a P , 0.05 vs. adult rats
b P , 0.05 vs. respective untreated group
c P , 0.05 vs. respective basal value
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with the observed beneficial vascular effects. Enhanced NO
availability seems to account for the observed vascular
effects of losartan in both age groups, because the enhance-
ments in Ach-induced relaxations were blunted in presence
of the NO synthase inhibitor, L-NAME. The participation
of enhanced NO availability in the actions of losartan is
indirectly supported by the increased urine excretion of
nitrites observed after losartan treatment. Previous results
support the involvement of NO in the actions of losartan in
SHR. We have already demonstrated that NO synthase
inhibition with L-NAME was able to block antihyperten-
sive, vascular and renal effects of losartan in SHR [30,
33–35]. Activation of AT2 receptors and angiotensin [1–7]
have been related with the increased NO availability and
endothelium-dependent relaxations during blockade of
AT1 receptors [30, 36, 37].
In contrast to NO, EDHF does not seem to be enhanced
by losartan treatment, regardless its principal mediatory
role in Ach-relaxations in MVB from untreated SHR. The
results also show that in elderly rats treated with losartan,
addition of indomethacin to the perfusion media already
containing L-NAME, reduced Ach-induced relaxations in a
similar extent as in untreated rats of the same age. These
data indicate that neither an increase in PGI2 nor a
reduction in an arachidonic acid-derived contracting factor
seem to account for the improvement produced by losartan
treatment on Ach-induced relaxations in MVB.
In summary, the present results demonstrated that the
deleterious consequences of aging on endothelium-depen-
dent relaxations induced by Ach in MVB from SHR are
due to reduced EDHF availability. The observed improve-
ment of endothelial function produced by losartan treat-
ment, suggests an important role of Ang II via AT1
receptors in the effects of aging in SHR. These beneficial
effects of losartan seem to be mainly dependent on an
increased NO availability.
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APPENDIX
Abbreviations used in this article are: Ach, acetylcholine; Ang II,
angiotensin II, AT1, angiotensin II type-1 receptor; BP, blood pressure;
EDCF, endothelium-derived contracting factor; EDHF, endothelium-
derived hyperpolarizing factor; L-NAME, NG-nitro-L-arginine methyl
Fig. 2. Concentration-response curves for relaxation induced by acethylcholine (10212 to 1027 mol) in isolated mesenteric vascular beds from adult
(A) and elderly (B) spontaneously hypertensive rats treated with losartan (10 mg/kg/day; E). Mesenteric vascular beds were precontracted with a
solution containing phenylephrine (1025 mol/liter) in the absence or presence of either L-NAME (1025 mol/liter; f) or L-NAME 1 indomethacin (1025
mol/L; ). Relaxations to acetylcholine in untreated rats are used as the control (F) or losartan (E) effect. The relaxation is expressed as percentage
of the reference constrictor response. Values express means 6 SEM. *P , 0 05 versus control group; #P , 0.05 versus losartan group. Bar graphs (insert)
represent the participation (arbitrary units) of EDHF, NO and PGS in the relaxation induced by acetylcholine in MVB from adult and elderly SHR
treated with losartan. Participation was calculated from the respective area under the curve in absence or presence of either L-NAME or L-NAME 1
indomethacin.
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ester; MVB, mesenteric vascular beds; NO, nitric oxide; PE, phenyleph-
rine; PGs, prostanoids; SHR, spontaneously hypertensive rat.
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